<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39457139</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9067</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Children (Basel, Switzerland)</Title><ISOAbbreviation>Children (Basel)</ISOAbbreviation></Journal><ArticleTitle>Proteomic Signatures of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Narrative Review.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1174</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/children11101174</ELocationID><Abstract><AbstractText Label="BACKGROUND/OBJECTIVES" NlmCategory="OBJECTIVE">Multisystem Inflammatory Syndrome in Children (MIS-C) is a post-infectious complication of COVID-19. MIS-C has overlapping features with other pediatric inflammatory disorders including Kawasaki Disease (KD), Macrophage Activation Syndrome (MAS), Toxic Shock Syndrome and sepsis. The exact mechanisms responsible for the clinical overlap between MIS-C and these conditions remain unclear, and biomarkers that could distinguish MIS-C from its clinical mimics are lacking. This study aimed to provide an overview of how proteomic methods, like Mass Spectrometry (MS) and affinity-based proteomics, can offer a detailed understanding of pathophysiology and aid in the diagnosis and prognosis of MIS-C.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A narrative review of relevant studies published up to July 2024 was conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified 15 studies and summarized their key proteomic findings. These studies investigated the serum or plasma proteome of MIS-C patients using MS, Proximity Extension, or Aptamer-based assays. The studies associated the proteomic profile of MIS-C with laboratory and clinical parameters and/or compared it with that of other diseases including acute COVID-19, KD, MAS, pediatric rheumatic diseases, sepsis and myocarditis or pericarditis following COVID-19 mRNA immunization. Depending on the method and the control group, different proteins were increased or decreased in the MIS-C group. The limitations and challenges in MIS-C proteomic research are also discussed, and future research recommendations are provided.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although proteomics appear to be a promising approach for understanding the pathogenesis and uncovering candidate biomarkers in MIS-C, proteomic studies are still needed to recognize and validate biomarkers that could accurately discriminate MIS-C from its clinical mimics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dourdouna</LastName><ForeName>Maria-Myrto</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Chemotherapy Research Laboratory, First Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatsi</LastName><ForeName>Elizabeth-Barbara</ForeName><Initials>EB</Initials><Identifier Source="ORCID">0000-0001-7325-6195</Identifier><AffiliationInfo><Affiliation>Infectious Diseases and Chemotherapy Research Laboratory, First Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syriopoulou</LastName><ForeName>Vasiliki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Infectious Diseases and Chemotherapy Research Laboratory, First Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michos</LastName><ForeName>Athanasios</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1745-1118</Identifier><AffiliationInfo><Affiliation>Infectious Diseases and Chemotherapy Research Laboratory, First Department of Pediatrics, Medical School, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, 11527 Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Children (Basel)</MedlineTA><NlmUniqueID>101648936</NlmUniqueID><ISSNLinking>2227-9067</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Kawasaki disease</Keyword><Keyword MajorTopicYN="N">MIS-C</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">biomarker</Keyword><Keyword MajorTopicYN="N">omics</Keyword><Keyword MajorTopicYN="N">proteomics</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39457139</ArticleId><ArticleId IdType="pmc">PMC11505985</ArticleId><ArticleId IdType="doi">10.3390/children11101174</ArticleId><ArticleId IdType="pii">children11101174</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hernández-García M., Roldan-Berengue E., Guitart C., Girona-Alarcón M., Argüello G., Pino R., De Sevilla M.F., García-García J.J., Jordan I. Multisystem inflammatory syndrome in children (MIS-C) and sepsis differentiation by a clinical and analytical score: MISSEP score. Eur. J. Pediatr. 2023;182:5109–5118. doi: 10.1007/s00431-023-05168-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-023-05168-w</ArticleId><ArticleId IdType="pmc">PMC10640430</ArticleId><ArticleId IdType="pubmed">37676491</ArticleId></ArticleIdList></Reference><Reference><Citation>Day-Lewis M., Berbert L., Baker A., Dionne A., Newburger J.W., Son M.B.F. Updated Case Definition of MIS-C and Implications for Clinical Care. Pediatrics. 2024;153:e2023063259. doi: 10.1542/peds.2023-063259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2023-063259</ArticleId><ArticleId IdType="pubmed">38204335</ArticleId></ArticleIdList></Reference><Reference><Citation>Waseem M., Shariff M.A., Tay E.T., Mortel D., Savadkar S., Lee H., Kondamudi N., Liang T. Multisystem Inflammatory Syndrome in Children. J. Emerg. Med. 2022;62:28–37. doi: 10.1016/j.jemermed.2021.07.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jemermed.2021.07.070</ArticleId><ArticleId IdType="pmc">PMC8445772</ArticleId><ArticleId IdType="pubmed">34538678</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacalone M., Scheier E., Shavit I. Multisystem inflammatory syndrome in children (MIS-C): A mini-review. Int. J. Emerg. Med. 2021;14:50. doi: 10.1186/s12245-021-00373-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12245-021-00373-6</ArticleId><ArticleId IdType="pmc">PMC8432439</ArticleId><ArticleId IdType="pubmed">34507521</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter A., Verweyen E.L., Queste E., Fuehner S., Jakob A., Masjosthusmann K., Hinze C., Wittkowski H., Foell D., Meinzer U., et al. Proteomic mapping identifies serum marker signatures associated with MIS-C specific hyperinflammation and cardiovascular manifestation. Clin. Immunol. 2024;264:110237. doi: 10.1016/j.clim.2024.110237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2024.110237</ArticleId><ArticleId IdType="pubmed">38723855</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoste L., Van Paemel R., Haerynck F. Multisystem inflammatory syndrome in children related to COVID-19: A systematic review. Eur. J. Pediatr. 2021;180:2019–2034. doi: 10.1007/s00431-021-03993-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-021-03993-5</ArticleId><ArticleId IdType="pmc">PMC7890544</ArticleId><ArticleId IdType="pubmed">33599835</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh S., Estrada-Rivadeneyra D., Jackson H., Keren I., Galassini R., Cooray S., Shah P., Agyeman P., Basmaci R., Carrol E., et al. Plasma Protein Biomarkers Distinguish Multisystem Inflammatory Syndrome in Children From Other Pediatric Infectious and Inflammatory Diseases. Pediatr. Infect. Dis. J. 2024;43:444–453. doi: 10.1097/INF.0000000000004267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000004267</ArticleId><ArticleId IdType="pmc">PMC11003410</ArticleId><ArticleId IdType="pubmed">38359342</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel J.M. Multisystem Inflammatory Syndrome in Children (MIS-C) Curr. Allergy Asthma Rep. 2022;22:53–60. doi: 10.1007/s11882-022-01031-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11882-022-01031-4</ArticleId><ArticleId IdType="pmc">PMC8938222</ArticleId><ArticleId IdType="pubmed">35314921</ArticleId></ArticleIdList></Reference><Reference><Citation>McCafferty C., Cai T., Borgel D., Lasne D., Renolleau S., Vedrenne-Cloquet M., Bonnet D., Wu J., Zaw T., Bhatnagar A., et al. Pathophysiological pathway differences in children who present with COVID-19 ARDS compared to COVID-19 induced MIS-C. Nat. Commun. 2022;13:2391. doi: 10.1038/s41467-022-29951-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-29951-9</ArticleId><ArticleId IdType="pmc">PMC9061738</ArticleId><ArticleId IdType="pubmed">35501302</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M.A., Fraser D.D., Daley M., Cepinskas G., Veraldi N., Grazioli S. The plasma proteome differentiates the multisystem inflammatory syndrome in children (MIS-C) from children with SARS-CoV-2 negative sepsis. Mol. Med. 2024;30:51. doi: 10.1186/s10020-024-00806-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-024-00806-x</ArticleId><ArticleId IdType="pmc">PMC11022403</ArticleId><ArticleId IdType="pubmed">38632526</ArticleId></ArticleIdList></Reference><Reference><Citation>Nygaard U., Nielsen A.B., Dungu K.H.S., Drici L., Holm M., Ottenheijm M.E., Nielsen A.B., Glenthøj J.P., Schmidt L.S., Cortes D., et al. Proteomic profiling reveals diagnostic signatures and pathogenic insights in multisystem inflammatory syndrome in children. Commun. Biol. 2024;7:688. doi: 10.1038/s42003-024-06370-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-024-06370-8</ArticleId><ArticleId IdType="pmc">PMC11153518</ArticleId><ArticleId IdType="pubmed">38839859</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui M., Cheng C., Zhang L. High-throughput proteomics: A methodological mini-review. Lab. Investig. 2022;102:1170–1181. doi: 10.1038/s41374-022-00830-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41374-022-00830-7</ArticleId><ArticleId IdType="pmc">PMC9362039</ArticleId><ArticleId IdType="pubmed">35922478</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y., Rex D.A.B., Schuster D., Neely B.A., Rosano G.L., Volkmar N., Momenzadeh A., Peters-Clarke T.M., Egbert S.B., Kreimer S., et al. Comprehensive Overview of Bottom-Up Proteomics using Mass Spectrometry. arXiv. 20232311.07791v1</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11348894</ArticleId><ArticleId IdType="pubmed">39193565</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaeeyan H., Arabfard M., Rasouli H.R., Shahriary A., Gh B.F.N.M. Evaluation of common protein biomarkers involved in the pathogenesis of respiratory diseases with proteomic methods: A systematic review. Immun. Inflamm. Dis. 2023;11:e1090. doi: 10.1002/iid3.1090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.1090</ArticleId><ArticleId IdType="pmc">PMC10659759</ArticleId><ArticleId IdType="pubmed">38018577</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck H.C., Overgaard M., Melholt Rasmussen L. Plasma proteomics to identify biomarkers—Application to cardiovascular diseases. Transl. Proteom. 2015;7:40–48. doi: 10.1016/j.trprot.2015.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trprot.2015.01.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu L., Guldiken N., Remih K., Karl A.S., Preisinger C., Strnad P. Serum/Plasma Proteome in Non-Malignant Liver Disease. Int. J. Mol. Sci. 2024;25:2008. doi: 10.3390/ijms25042008.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25042008</ArticleId><ArticleId IdType="pmc">PMC10889128</ArticleId><ArticleId IdType="pubmed">38396688</ArticleId></ArticleIdList></Reference><Reference><Citation>Birhanu A.G. Mass spectrometry-based proteomics as an emerging tool in clinical laboratories. Clin. Proteom. 2023;20:32. doi: 10.1186/s12014-023-09424-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12014-023-09424-x</ArticleId><ArticleId IdType="pmc">PMC10464495</ArticleId><ArticleId IdType="pubmed">37633929</ArticleId></ArticleIdList></Reference><Reference><Citation>Godfred-Cato S., Bryant B., Leung J., Oster M.E., Conklin L., Abrams J., Roguski K., Wallace B., Prezzato E., Koumans E.H., et al. COVID-19–Associated Multisystem Inflammatory Syndrome in Children—United States, March–July 2020. MMWR. Morb. Mortal. Wkly. Rep. 2020;69:1074–1080. doi: 10.15585/mmwr.mm6932e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6932e2</ArticleId><ArticleId IdType="pmc">PMC7440126</ArticleId><ArticleId IdType="pubmed">32790663</ArticleId></ArticleIdList></Reference><Reference><Citation>Son M.B.F., Burns J.C., Newburger J.W. A New Definition for Multisystem Inflammatory Syndrome in Children. Pediatrics. 2023;151:e2022060302. doi: 10.1542/peds.2022-060302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2022-060302</ArticleId><ArticleId IdType="pubmed">36624565</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed M., Advani S., Moreira A., Zoretic S., Martinez J., Chorath K., Acosta S., Naqvi R., Burmeister-Morton F., Burmeister F., et al. Multisystem inflammatory syndrome in children: A systematic review. EClinicalMedicine. 2020;26:100527. doi: 10.1016/j.eclinm.2020.100527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2020.100527</ArticleId><ArticleId IdType="pmc">PMC7473262</ArticleId><ArticleId IdType="pubmed">32923992</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu E.Y., Campbell M.J. Cardiac Manifestations of Multisystem Inflammatory Syndrome in Children (MIS-C) Following COVID-19. Curr. Cardiol. Rep. 2021;23:168. doi: 10.1007/s11886-021-01602-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11886-021-01602-3</ArticleId><ArticleId IdType="pmc">PMC8486157</ArticleId><ArticleId IdType="pubmed">34599465</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Smith J.J., Verweyen E.L., Clay G.M., Esteban Y.M., de Loizaga S.R., Baker E.J., Do T., Dhakal S., Lang S.M., Grom A.A., et al. Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: A cohort study. Lancet Rheumatol. 2021;3:e574–e584. doi: 10.1016/S2665-9913(21)00139-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00139-9</ArticleId><ArticleId IdType="pmc">PMC8186852</ArticleId><ArticleId IdType="pubmed">34124694</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection 2023 Case Definition.  [(accessed on 5 August 2024)]; Available online:  https://ndc.services.cdc.gov/case-definitions/multisystem-inflammatory-syndrome-in-children-mis-c-2023/</Citation></Reference><Reference><Citation>Sen E.S., Clarke S.L., Ramanan A.V. Macrophage Activation Syndrome. Indian. J. Pediatr. 2016;83:248–253. doi: 10.1007/s12098-015-1877-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12098-015-1877-1</ArticleId><ArticleId IdType="pubmed">26400031</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Zheng Q., Zou L., Wu J., Guo L., Teng L., Zheng R., Jung L.K.L., Lu M. Kawasaki disease shock syndrome: Clinical characteristics and possible use of IL-6, IL-10 and IFN-γ as biomarkers for early recognition. Pediatr. Rheumatol. Online J. 2019;17:1. doi: 10.1186/s12969-018-0303-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-018-0303-4</ArticleId><ArticleId IdType="pmc">PMC6321686</ArticleId><ArticleId IdType="pubmed">30611297</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J., Bae K.S., Rhim J.W., Lee S.Y., Jeong D.C., Kang J.H. Macrophage Activation Syndrome in Children: Update on Diagnosis and Treatment. Children. 2024;11:755. doi: 10.3390/children11070755.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children11070755</ArticleId><ArticleId IdType="pmc">PMC11274371</ArticleId><ArticleId IdType="pubmed">39062205</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravelli A., Minoia F., Davì S., Horne A., Bovis F., Pistorio A., Aricò M., Avcin T., Behrens E.M., De Benedetti F., et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;68:566–576. doi: 10.1002/art.39332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39332</ArticleId><ArticleId IdType="pubmed">26314788</ArticleId></ArticleIdList></Reference><Reference><Citation>McCrindle B.W., Rowley A.H., Newburger J.W., Burns J.C., Bolger A.F., Gewitz M., Baker A.L., Jackson M.A., Takahashi M., Shah P.B., et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;135:e927–e999. doi: 10.1161/CIR.0000000000000484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000484</ArticleId><ArticleId IdType="pubmed">28356445</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein B., Giroir B., Randolph A. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr. Crit. Care Med. 2005;6:2–8. doi: 10.1097/01.PCC.0000149131.72248.E6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000149131.72248.E6</ArticleId><ArticleId IdType="pubmed">15636651</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda M., Nadel S. Pediatric Sepsis: A Summary of Current Definitions and Management Recommendations. Curr. Pediatr. Rep. 2023;11:29–39. doi: 10.1007/s40124-023-00286-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40124-023-00286-3</ArticleId><ArticleId IdType="pmc">PMC10169116</ArticleId><ArticleId IdType="pubmed">37252329</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  Toxic Shock Syndrome (Other Than Streptococcal) (TSS). 2011 Case Definition.  [(accessed on 19 September 2024)]; Available online:  https://ndc.services.cdc.gov/case-definitions/toxic-shock-syndrome-2011/</Citation></Reference><Reference><Citation>CDC  Streptococcal Toxic Shock Syndrome (STSS) (Streptococcus pyogenes) 2010 Case Definition.  [(accessed on 19 September 2024)]; Available online:  https://ndc.services.cdc.gov/case-definitions/streptococcal-toxic-shock-syndrome-2010/</Citation></Reference><Reference><Citation>Tebani A., Afonso C., Marret S., Bekri S. Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations. Int. J. Mol. Sci. 2016;17:1555. doi: 10.3390/ijms17091555.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms17091555</ArticleId><ArticleId IdType="pmc">PMC5037827</ArticleId><ArticleId IdType="pubmed">27649151</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurke R., Bendes A., Bowes J., Koehm M., Twyman R.M., Barton A., Elewaut D., Goodyear C., Hahnefeld L., Hillenbrand R., et al. Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis. Biomedicines. 2022;10:2387. doi: 10.3390/biomedicines10102387.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10102387</ArticleId><ArticleId IdType="pmc">PMC9598654</ArticleId><ArticleId IdType="pubmed">36289648</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Wang J., Pan D., Wang X., Xu Y., Yan J., Wang L., Yang X., Yang M., Liu G.P. Applications of multi-omics analysis in human diseases. MedComm. 2023;4:e315. doi: 10.1002/mco2.315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.315</ArticleId><ArticleId IdType="pmc">PMC10390758</ArticleId><ArticleId IdType="pubmed">37533767</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Amrani S., Al-Jabri Z., Al-Zaabi A., Alshekaili J., Al-Khabori M. Proteomics: Concepts and applications in human medicine. World J. Biol. Chem. 2021;12:57–69. doi: 10.4331/wjbc.v12.i5.57.</Citation><ArticleIdList><ArticleId IdType="doi">10.4331/wjbc.v12.i5.57</ArticleId><ArticleId IdType="pmc">PMC8473418</ArticleId><ArticleId IdType="pubmed">34630910</ArticleId></ArticleIdList></Reference><Reference><Citation>Consiglio C.R., Cotugno N., Sardh F., Pou C., Amodio D., Rodriguez L., Tan Z., Zicari S., Ruggiero A., Pascucci G.R., et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183:968–981.e7. doi: 10.1016/j.cell.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7474869</ArticleId><ArticleId IdType="pubmed">32966765</ArticleId></ArticleIdList></Reference><Reference><Citation>Diorio C., Shraim R., Vella L.A., Giles J.R., Baxter A.E., Oldridge D.A., Canna S.W., Henrickson S.E., McNerney K.O., Balamuth F., et al. Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. Nat. Commun. 2021;12:7222. doi: 10.1038/s41467-021-27544-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27544-6</ArticleId><ArticleId IdType="pmc">PMC8664884</ArticleId><ArticleId IdType="pubmed">34893640</ArticleId></ArticleIdList></Reference><Reference><Citation>Porritt R.A., Binek A., Paschold L., Rivas M.N., McArdle A., Yonker L.M., Alter G., Chandnani H.K., Lopez M., Fasano A., et al. The autoimmune signature of hyperinflammatory multisystem inflammatory syndrome in children. J. Clin. Investig. 2021;131:e151520. doi: 10.1172/JCI151520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI151520</ArticleId><ArticleId IdType="pmc">PMC8516454</ArticleId><ArticleId IdType="pubmed">34437303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswamy A., Brodsky N.N., Sumida T.S., Comi M., Asashima H., Hoehn K.B., Li N., Liu Y., Shah A., Ravindra N.G., et al. Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity. 2021;54:1083–1095.e7. doi: 10.1016/j.immuni.2021.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.04.003</ArticleId><ArticleId IdType="pmc">PMC8043654</ArticleId><ArticleId IdType="pubmed">33891889</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacco K., Castagnoli R., Vakkilainen S., Liu C., Delmonte O.M., Oguz C., Kaplan I.M., Alehashemi S., Burbelo P.D., Bhuyan F., et al. Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. Nat. Med. 2022;28:1050–1062. doi: 10.1038/s41591-022-01724-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01724-3</ArticleId><ArticleId IdType="pmc">PMC9119950</ArticleId><ArticleId IdType="pubmed">35177862</ArticleId></ArticleIdList></Reference><Reference><Citation>Druzak S., Iffrig E., Roberts B.R., Zhang T., Fibben K.S., Sakurai Y., Verkerke H.P., Rostad C.A., Chahroudi A., Schneider F., et al. Multiplatform analyses reveal distinct drivers of systemic pathogenesis in adult versus pediatric severe acute COVID-19. Nat. Commun. 2023;14:1638. doi: 10.1038/s41467-023-37269-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37269-3</ArticleId><ArticleId IdType="pmc">PMC10073144</ArticleId><ArticleId IdType="pubmed">37015925</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber C.N., Patel R.S., Trachtman R., Lepow L., Amanat F., Krammer F., Wilson K.M., Onel K., Geanon D., Tuballes K., et al. Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) Cell. 2020;183:982–995.e14. doi: 10.1016/j.cell.2020.09.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.034</ArticleId><ArticleId IdType="pmc">PMC7489877</ArticleId><ArticleId IdType="pubmed">32991843</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonker L.M., Gilboa T., Ogata A.F., Senussi Y., Lazarovits R., Boribong B.P., Bartsch Y.C., Loiselle M., Rivas M.N., Porritt R.A., et al. Multisystem inflammatory syndrome in children is driven by zonulin-dependent loss of gut mucosal barrier. J. Clin. Investig. 2021;131:e149633. doi: 10.1172/JCI149633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI149633</ArticleId><ArticleId IdType="pmc">PMC8279585</ArticleId><ArticleId IdType="pubmed">34032635</ArticleId></ArticleIdList></Reference><Reference><Citation>Amodio D., Pascucci G.R., Cotugno N., Rossetti C., Manno E.C., Pighi C., Morrocchi E., D'Alessandro A., Perrone M.A., Valentini A., et al. Similarities and differences between myocarditis following COVID-19 mRNA vaccine and multiple inflammatory syndrome with cardiac involvement in children. Clin. Immunol. 2023;255:109751. doi: 10.1016/j.clim.2023.109751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2023.109751</ArticleId><ArticleId IdType="pubmed">37660743</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodeur K.E., Liu M., Ibanez D., de Groot M.J., Chen L., Du Y., Seyal E., Laza-Briviesca R., Baker A., Chang J.C., et al. Elevation of IL-17 cytokines distinguishes Kawasaki disease from other pediatric inflammatory disorders. Arthritis Rheumatol. 2023;76:285–292. doi: 10.1002/art.42680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42680</ArticleId><ArticleId IdType="pmc">PMC10842426</ArticleId><ArticleId IdType="pubmed">37610270</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulling A.J., Holierhoek M.G., Jansen-Hoogendijk A.M., Hoste L., Haerynck F., Tavernier S.J., Oostenbrink R., Buysse C.M.P., Bannier M., Bekhof J., et al. Serum proteomics reveals hemophagocytic lymphohistiocytosis-like phenotype in a subset of patients with multisystem inflammatory syndrome in children. Clin. Immunol. 2024;264:110252. doi: 10.1016/j.clim.2024.110252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2024.110252</ArticleId><ArticleId IdType="pubmed">38744408</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y., Yeon S.Y., Qian C., You S., Yang W. On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances. Int. J. Mol. Sci. 2021;22:13537. doi: 10.3390/ijms222413537.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222413537</ArticleId><ArticleId IdType="pmc">PMC8703658</ArticleId><ArticleId IdType="pubmed">34948334</ArticleId></ArticleIdList></Reference><Reference><Citation>Gobena S., Admassu B., Kinde M.Z., Gessese A.T. Proteomics and Its Current Application in Biomedical Area: Concise Review. Sci. World J. 2024;2024:4454744. doi: 10.1155/2024/4454744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2024/4454744</ArticleId><ArticleId IdType="pmc">PMC10894052</ArticleId><ArticleId IdType="pubmed">38404932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Fonslow B.R., Shan B., Baek M.C., Yates J.R., 3rd Protein analysis by shotgun/bottom-up proteomics. Chem. Rev. 2013;113:2343–2394. doi: 10.1021/cr3003533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/cr3003533</ArticleId><ArticleId IdType="pmc">PMC3751594</ArticleId><ArticleId IdType="pubmed">23438204</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasin Y., Seldin M., Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18:83. doi: 10.1186/s13059-017-1215-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-017-1215-1</ArticleId><ArticleId IdType="pmc">PMC5418815</ArticleId><ArticleId IdType="pubmed">28476144</ArticleId></ArticleIdList></Reference><Reference><Citation>McArdle A.J., Menikou S. What is proteomics? Arch. Dis. Child. Educ. Pr. Ed. 2021;106:178–181. doi: 10.1136/archdischild-2019-317434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2019-317434</ArticleId><ArticleId IdType="pubmed">32241812</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpievitch Y.V., Polpitiya A.D., Anderson G.A., Smith R.D., Dabney A.R. Liquid Chromatography Mass Spectrometry-Based Proteomics: Biological and Technological Aspects. Ann. Appl. Stat. 2010;4:1797–1823. doi: 10.1214/10-AOAS341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1214/10-AOAS341</ArticleId><ArticleId IdType="pmc">PMC3095207</ArticleId><ArticleId IdType="pubmed">21593992</ArticleId></ArticleIdList></Reference><Reference><Citation>Baldan-Martin M., Chaparro M., Gisbert J.P. Systematic Review: Urine Biomarker Discovery for Inflammatory Bowel Disease Diagnosis. Int. J. Mol. Sci. 2023;24:10159. doi: 10.3390/ijms241210159.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241210159</ArticleId><ArticleId IdType="pmc">PMC10299330</ArticleId><ArticleId IdType="pubmed">37373307</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenk D., Zuo C., Kislinger T., Sepiashvili L. Recent developments in mass-spectrometry-based targeted proteomics of clinical cancer biomarkers. Clin. Proteom. 2024;21:6. doi: 10.1186/s12014-024-09452-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12014-024-09452-1</ArticleId><ArticleId IdType="pmc">PMC10826105</ArticleId><ArticleId IdType="pubmed">38287260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuku K.O., Oyetoro R., Hashemian M., Livinski A.A., Shearer J.J., Joo J., Psaty B.M., Levy D., Ganz P., Roger V.L. Proteomics for heart failure risk stratification: A systematic review. BMC Med. 2024;22:34. doi: 10.1186/s12916-024-03249-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-024-03249-7</ArticleId><ArticleId IdType="pmc">PMC10809595</ArticleId><ArticleId IdType="pubmed">38273315</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoevesandt O., Taussig M.J. Affinity proteomics: The role of specific binding reagents in human proteome analysis. Expert. Rev. Proteom. 2012;9:401–414. doi: 10.1586/epr.12.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/epr.12.34</ArticleId><ArticleId IdType="pubmed">22967077</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar-Mahecha A., Kuzyk M.A., Domanski D., Borchers C.H., Basik M. The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines. PLoS ONE. 2012;7:e38290. doi: 10.1371/journal.pone.0038290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0038290</ArticleId><ArticleId IdType="pmc">PMC3368926</ArticleId><ArticleId IdType="pubmed">22701622</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakayasu E.S., Gritsenko M., Piehowski P.D., Gao Y., Orton D.J., Schepmoes A.A., Fillmore T.L., Frohnert B.I., Rewers M., Krischer J.P., et al. Tutorial: Best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation. Nat. Protoc. 2021;16:3737–3760. doi: 10.1038/s41596-021-00566-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-021-00566-6</ArticleId><ArticleId IdType="pmc">PMC8830262</ArticleId><ArticleId IdType="pubmed">34244696</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerszten R.E., Accurso F., Bernard G.R., Caprioli R.M., Klee E.W., Klee G.G., Kullo I., Laguna T.A., Roth F.P., Sabatine M., et al. Challenges in translating plasma proteomics from bench to bedside: Update from the NHLBI Clinical Proteomics Programs. Am. J. Physiol. Lung Cell Mol. Physiol. 2008;295:L16–L22. doi: 10.1152/ajplung.00044.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00044.2008</ArticleId><ArticleId IdType="pmc">PMC2494793</ArticleId><ArticleId IdType="pubmed">18456800</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S.L., Tyagi R., Dhar A., Oswal N., Khandelwal A., Jaiswal R.K. Children’s SARS-CoV-2 Infection and Their Vaccination. Vaccines. 2023;11:418. doi: 10.3390/vaccines11020418.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11020418</ArticleId><ArticleId IdType="pmc">PMC9962844</ArticleId><ArticleId IdType="pubmed">36851295</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold D.M., Patriquin C.J., Nazy I. Thrombotic microangiopathies: A general approach to diagnosis and management. CMAJ. 2017;189:E153–E159. doi: 10.1503/cmaj.160142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.160142</ArticleId><ArticleId IdType="pmc">PMC5266569</ArticleId><ArticleId IdType="pubmed">27754896</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalçacıoğlu H., Önal H.G., Bozkaya Yücel B., Tekcan Karali D., Erdeniz E., Öz Tuncer G., Aydoğ Ö. Case report: Thrombotic microangiopathy in pediatric multisystem inflammatory syndrome associated with COVID-19: A case series. Front. Pediatr. 2023;11:1254308. doi: 10.3389/fped.2023.1254308.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2023.1254308</ArticleId><ArticleId IdType="pmc">PMC10602901</ArticleId><ArticleId IdType="pubmed">37900680</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmoud S., El-Kalliny M., Kotby A., El-Ganzoury M., Fouda E., Ibrahim H. Treatment of MIS-C in Children and Adolescents. Curr. Pediatr. Rep. 2022;10:1–10. doi: 10.1007/s40124-021-00259-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40124-021-00259-4</ArticleId><ArticleId IdType="pmc">PMC8741532</ArticleId><ArticleId IdType="pubmed">35036079</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC  Clinical Treatment of Multisystem Inflammatory Syndrome in Children.  [(accessed on 12 August 2024)]; Available online:  https://www.cdc.gov/mis/hcp/clinical-care-treatment/index.html.</Citation></Reference><Reference><Citation>Nadig P.L., Joshi V., Pilania R.K., Kumrah R., Kabeerdoss J., Sharma S., Suri D., Rawat A., Singh S. Intravenous Immunoglobulin in Kawasaki Disease-Evolution and Pathogenic Mechanisms. Diagnostics. 2023;13:2338. doi: 10.3390/diagnostics13142338.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics13142338</ArticleId><ArticleId IdType="pmc">PMC10378342</ArticleId><ArticleId IdType="pubmed">37510082</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai J.H., Tang M., Zhang H.X., Dan Luo E., Zhang R., Shuai S.P., Liang H., Tao W.J., Wu M.J., Wen Y., et al. Therapeutic Window of Intravenous Immunoglobulin (IVIG) and its correlation with IVIG-resistant in Kawasaki Disease: A retrospective study. J. Pediatr. 2023;99:161–167. doi: 10.1016/j.jped.2022.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jped.2022.07.003</ArticleId><ArticleId IdType="pmc">PMC10031361</ArticleId><ArticleId IdType="pubmed">35995125</ArticleId></ArticleIdList></Reference><Reference><Citation>Dusser P., Belot A., Bajolle F., Kevorkian-Verguet C., Meinzer U., Huet F., Tiriau S., Kone-Paut I. Subcutaneous anakinra in the management of refractory MIS-C in France. Front. Pediatr. 2024;12:1270878. doi: 10.3389/fped.2024.1270878.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2024.1270878</ArticleId><ArticleId IdType="pmc">PMC10920278</ArticleId><ArticleId IdType="pubmed">38464895</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai C.-M., Lin C.-H.R., Kuo H.-C., Cheng F.-J., Yu H.-R., Hung T.-C., Hung C.-S., Huang C.-M., Chu Y.-C., Huang Y.-H. Use of Machine Learning to Differentiate Children with Kawasaki Disease from Other Febrile Children in a Pediatric Emergency Department. JAMA Netw. Open. 2023;6:e237489. doi: 10.1001/jamanetworkopen.2023.7489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.7489</ArticleId><ArticleId IdType="pmc">PMC10091152</ArticleId><ArticleId IdType="pubmed">37040115</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhary H., Nameirakpam J., Kumrah R., Pandiarajan V., Suri D., Rawat A., Singh S. Biomarkers for Kawasaki Disease: Clinical Utility and the Challenges Ahead. Front. Pediatr. 2019;7:242. doi: 10.3389/fped.2019.00242.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2019.00242</ArticleId><ArticleId IdType="pmc">PMC6591436</ArticleId><ArticleId IdType="pubmed">31275907</ArticleId></ArticleIdList></Reference><Reference><Citation>Noval Rivas M., Arditi M. Kawasaki Disease and Multisystem Inflammatory Syndrome in Children. Rheum. Dis. Clin. North. Am. 2023;49:647–659. doi: 10.1016/j.rdc.2023.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2023.03.002</ArticleId><ArticleId IdType="pmc">PMC10020039</ArticleId><ArticleId IdType="pubmed">37331738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin I.C., Suen J.L., Huang S.K., Chou M.H., Kuo H.C., Lo M.H., Kuo K.C., Wang L. Involvement of IL-17 A/IL-17 Receptor A with Neutrophil Recruitment and the Severity of Coronary Arteritis in Kawasaki Disease. J. Clin. Immunol. 2024;44:77. doi: 10.1007/s10875-024-01673-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-024-01673-1</ArticleId><ArticleId IdType="pmc">PMC10920475</ArticleId><ArticleId IdType="pubmed">38451335</ArticleId></ArticleIdList></Reference><Reference><Citation>Nie L., Guo X., Esmailzadeh L., Zhang J., Asadi A., Collinge M., Li X., Kim J.D., Woolls M., Jin S.W., et al. Transmembrane protein ESDN promotes endothelial VEGF signaling and regulates angiogenesis. J. Clin. Investig. 2013;123:5082–5097. doi: 10.1172/JCI67752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI67752</ArticleId><ArticleId IdType="pmc">PMC3859420</ArticleId><ArticleId IdType="pubmed">24177422</ArticleId></ArticleIdList></Reference><Reference><Citation>Poniecka A., Smolewska E. A fine line between macrophage activation syndrome and multisystem inflammatory syndrome in children—Literature review based on two case reports. Reumatologia. 2021;59:47–57. doi: 10.5114/reum.2021.102871.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/reum.2021.102871</ArticleId><ArticleId IdType="pmc">PMC7944956</ArticleId><ArticleId IdType="pubmed">33707796</ArticleId></ArticleIdList></Reference><Reference><Citation>Buda P., Strauss E., Januszkiewicz-Lewandowska D., Czerwinska E., Ludwikowska K., Szenborn L., Gowin E., Okarska-Napierała M., Kuchar E., Ksia̧Zyk J. Clinical characteristics of children with MIS-C fulfilling classification criteria for macrophage activation syndrome. Front. Pediatr. 2022;10:981711. doi: 10.3389/fped.2022.981711.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.981711</ArticleId><ArticleId IdType="pmc">PMC9520614</ArticleId><ArticleId IdType="pubmed">36186637</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulert G.S., Grom A.A. Macrophage activation syndrome and cytokine-directed therapies. Best. Pr. Res. Clin. Rheumatol. 2014;28:277–292. doi: 10.1016/j.berh.2014.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2014.03.002</ArticleId><ArticleId IdType="pmc">PMC4074772</ArticleId><ArticleId IdType="pubmed">24974063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojan A., Parvu A., Zsoldos I.A., Torok T., Farcas A.D. Macrophage activation syndrome: A diagnostic challenge (Review) Exp. Ther. Med. 2021;22:904. doi: 10.3892/etm.2021.10336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2021.10336</ArticleId><ArticleId IdType="pmc">PMC8243343</ArticleId><ArticleId IdType="pubmed">34257717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ailioaie L.M., Ailioaie C., Litscher G. Biomarkers in Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome and Their Importance in COVID Era. Int. J. Mol. Sci. 2022;23:12757. doi: 10.3390/ijms232112757.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232112757</ArticleId><ArticleId IdType="pmc">PMC9655921</ArticleId><ArticleId IdType="pubmed">36361547</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapani S., Rubino C., Lasagni D., Pegoraro F., Resti M., Simonini G., Indolfi G. Thromboembolic complications in children with COVID-19 and MIS-C: A narrative review. Front. Pediatr. 2022;10:944743. doi: 10.3389/fped.2022.944743.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.944743</ArticleId><ArticleId IdType="pmc">PMC9402981</ArticleId><ArticleId IdType="pubmed">36034557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanziotti V.S., Póvoa P., Soares M., Silva J.R., Barbosa A.P., Salluh J.I. Use of biomarkers in pediatric sepsis: Literature review. Rev. Bras. Ter. Intensiv. 2016;28:472–482. doi: 10.5935/0103-507X.20160080.</Citation><ArticleIdList><ArticleId IdType="doi">10.5935/0103-507X.20160080</ArticleId><ArticleId IdType="pmc">PMC5225923</ArticleId><ArticleId IdType="pubmed">28099644</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazlollahi A., Zahmatyar M., Noori M., Nejadghaderi S.A., Sullman M.J.M., Shekarriz-Foumani R., Kolahi A.A., Singh K., Safiri S. Cardiac complications following mRNA COVID-19 vaccines: A systematic review of case reports and case series. Rev. Med. Virol. 2022;32:e2318. doi: 10.1002/rmv.2318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2318</ArticleId><ArticleId IdType="pubmed">34921468</ArticleId></ArticleIdList></Reference><Reference><Citation>Buoninfante A., Andeweg A., Genov G., Cavaleri M. Myocarditis associated with COVID-19 vaccination. NPJ Vaccines. 2024;9:122. doi: 10.1038/s41541-024-00893-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-024-00893-1</ArticleId><ArticleId IdType="pmc">PMC11213864</ArticleId><ArticleId IdType="pubmed">38942751</ArticleId></ArticleIdList></Reference><Reference><Citation>La Torre F., Taddio A., Conti C., Cattalini M. Multi-Inflammatory Syndrome in Children (MIS-C) in 2023: Is It Time to Forget about It? Children. 2023;10:980. doi: 10.3390/children10060980.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/children10060980</ArticleId><ArticleId IdType="pmc">PMC10297102</ArticleId><ArticleId IdType="pubmed">37371212</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamad Saied M., van der Griend L., van Straalen J.W., Wulffraat N.M., Vastert S., Jansen M.H.A. The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): A systematic literature review and meta-analysis. Pediatr. Rheumatol. Online J. 2023;21:80. doi: 10.1186/s12969-023-00848-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12969-023-00848-1</ArticleId><ArticleId IdType="pmc">PMC10405572</ArticleId><ArticleId IdType="pubmed">37550719</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Xue M., Hu Y., Li J., Li Z., Wang Y. Proteomic Insights into Osteoporosis: Unraveling Diagnostic Markers of and Therapeutic Targets for the Metabolic Bone Disease. Biomolecules. 2024;14:554. doi: 10.3390/biom14050554.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom14050554</ArticleId><ArticleId IdType="pmc">PMC11118602</ArticleId><ArticleId IdType="pubmed">38785961</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>